Zhang, Y., Ishida, C., Karpel-Massler, G., & Siegelin, M. (2018). CBMT-37. FDA-APPROVED HDAC INHIBITORS ANTAGONIZE THE WARBURG EFFECT AND CAUSE UNIQUE METABOLIC VULNERABILITIES. Neuro Oncol.
Citação norma ChicagoZhang, Yiru, Chiaki Ishida, Georg Karpel-Massler, and Markus Siegelin. "CBMT-37. FDA-APPROVED HDAC INHIBITORS ANTAGONIZE THE WARBURG EFFECT AND CAUSE UNIQUE METABOLIC VULNERABILITIES." Neuro Oncol 2018.
MLA CitationZhang, Yiru, Chiaki Ishida, Georg Karpel-Massler, and Markus Siegelin. "CBMT-37. FDA-APPROVED HDAC INHIBITORS ANTAGONIZE THE WARBURG EFFECT AND CAUSE UNIQUE METABOLIC VULNERABILITIES." Neuro Oncol 2018.
Advarsel: Disse citationer er muligvist ikke 100% nøjagtige.